Labs and the bigger picture
In individuals with T2DM and MASLD, glucose-lowering medications other than GLP-1RAs or pioglitazone, such as sulfonylureas, dipeptidyl peptidase-4 inhibitors, acarbose, or insulin, can be used for glycemic management when clinically indicated (American Diabetes Association Professional Practice Committee for Diabetes*, 2025[2])
has also received CME-related honoraria or consulting fees from CASEN Recordati, Organon, Lundbeck, and the Academy for Continuing Medical Education (Akademijazakme), with no financial or other conflicts of interest relevant to the subject of this article
Some patients also ask about stretching a prescription with lower doses, which saves money but has no trial support
By Healthogenics
Firstly, the majority of reports lack evidence establishing a causal link between the reported AE and drug exposure